Vibrio cholerae 01, the etiological agent of cholera, causes severe diarrhea in infected humans following colonization of the small intestine and production of an enterotoxin, cholera toxin. In V. cholerae 01, the cholera toxin structural genes (ctxAB) are chromosomal. Attenuated live oral vaccines have been derived by constructing defined deletion mutants unable to express the ADP-ribosylating A subunit of cholera toxin but still capable of producing the immunogenic B subunit (11, 14, 22) . One such isogenic mutant, CVD103, a derivative of classical Inaba strain 569B, is significantly less reactogenic than are strains tested previously and confers protection against rechallenge with homologous and heterologous virulent V. cholerae 01 (13) . The theoretical possibility exists that following conjugation or transduction in either the gastrointestinal tract or the environment, the mutated ctx gene could regain the deleted sequences by recombination of homologous flanking DNA sequences (15, 17, 27, 30) .
The RecA protein plays an important part in homologous recombination in Escherichia coli (19, 31, 32) . E. coli recA mutants have 10-3 to 10-6 the recombination frequency observed with wild-type strains (5, 7) . A RecA protein with seemingly identical functions has been identified in V. cholerae 01, and the gene encoding this function has been cloned (5, 9, 28) . Thus, recA mutations could theoretically have an important function in attenuated vaccine strains, as previously suggested by Goldberg and Mekalanos (5) . To address the theoretical potential for reacquisition of proficient ctx genes, we constructed a derivative of the attenuated V. cholerae 01 strain CVD103 (CVD103RM), which was deficient in its ability to recombine homologous DNA sequences into the chromosome.
V. cholerae 01 chromosomal DNA from strain 569B (18), digested with EcoRI, was cloned into pBR322 and a clone containing the recA gene was selected by complementation in E. coli strain HB101 (recA). The resulting plasmid, pCVD839, contained an approximately 7-kilobase EcoRI DNA fragment which conferred resistance to methyl methanesulfonate (5) (Fig. 1) . A frameshift mutation was constructed in the recA gene by the ligation of an 8-base-pair synthetic oligonucleotide containing the restriction site KpnI into pCVD839 digested with RsaI under conditions empirically found to produce plasmid linears (Fig. 1) . The insertion mutation in pCVD842 was identified by screening for the loss of resistance to methyl methanesulfonate and was confirmed by restriction analysis.
Following mobilization of pCVD842 into CVD103 with the conjugal plasmid pRK2013 (4) (Fig. 1 (Fig. 2) . A spontaneous streptomycin-resistant derivative of CVD103 RM named CVD103RMSR was isolated in order to assist in the future identification and differentiation of the vaccine strain from wild-type V. cholerae 01.
To assess the effect of the recA mutation on CVD103RM, community volunteers were immunized orally with CVD-103RM and CVD103RMSR (Table 1) . Volunteer studies were carried out under legal quarantine in the 32-bed isolation ward maintained by the Center for Vaccine Development in the University of Maryland Hospital (Baltimore, Md.) and were approved by the Human Volunteers Research Committee of the University of Maryland at Baltimore. The methods of medical screening, volunteer care, informed consent, stool cultures, and duodenal gelatin string cultures are described elsewhere (10, 13, 14, 23) . The immunizing dose was administered orally following neutralization of gastric acid as previously described (10, 13, 14, 23 human intestine by V. cholerae 01 is incompletely understood; one factor, the toxin coregulated pilus (TCP) (34) , is clearly involved in colonization (10), but several other fimbriae (8) and accessory colonization factors (29) could potentially play a role in this process. In Serratia marcescens, a variety of extracellular proteins, such as nuclease, chitinase, and lipase, require a functional recA gene for expression (1) . V. cholerae could conceivably require recA for expression of surface colonization factors. Finally, recAdependent in vivo amplification of the ctx genetic element during passage in rabbits has been demonstrated for V. cholerae 01 (6, 20) . In the El Tor biotype, amplification requires one or more copies of the transposable RS1 genetic element flanking the ctx genes (20) . (Amplification of ctx has not been reported in the classical biotype, which contains RS1 only on one side of ctx [21] .) It is possible that undescribed RS1-like genetic elements duplicated in a recAdependent manner may contain genes which affect colonization. In this case, a recA mutant could be at a disadvantage in the intestine. Both 569B and CVD103RM have been shown to produce toxin coregulated pilus (8; R. H. Hall, unpublished data) but it has not been reported whether these genes are associated with an amplifiable genetic element.
An alternative mutation to assist in addressing concerns about environmental release would be an assayable marker to distinguish the live attenuated vaccine strain from wildtype V. cholerae 01. As the use of an antibiotic resistance marker would be inadvisable, we have introduced a mercury resistance operon (mer) into the unexpressed hlyA gene of CVD103. The resulting strain, CVD103-HgR, has been tested in closed environments in adult volunteers at the Center for Vaccine Development in Baltimore (13) University). Given the negative effect of the recA mutation on V. cholerae CVD103, the mer marker has proven to be more useful than the recA mutation for addressing some of the concerns about environmental release of a live vaccine strain. However, it is conceivable that with future vaccine strains that exhibit a higher propensity for intestinal colonization, recA mutants may yet play a role in live oral V. cholerae vaccines.
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